Natasha Bing
Gerontology · Shenandoah, TXNPI 1033751672
Payments from drug & device makers
Across 80 payments — averaging $20.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$255
- Endo USA, Inc.$248
- Axonics, Inc.$205
- Sumitomo Pharma America, Inc.$161
- Astellas Pharma US Inc$152
- C. R. Bard, Inc. & Subsidiaries$138
- plus $500 from 16 others
What the payments were for
- Food & beverage$1,48590%
- Education$17310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 10 | $255 |
| Endo USA, Inc. | 7 | $248 |
| Axonics, Inc. | 3 | $205 |
| Sumitomo Pharma America, Inc. | 12 | $161 |
| Astellas Pharma US Inc | 4 | $152 |
| C. R. Bard, Inc. & Subsidiaries | 22 | $138 |
| Dexcom, Inc. | 3 | $67 |
| Boston Scientific | 2 | $66 |
| Dendreon Pharmaceuticals LLC | 2 | $62 |
| Bayer | 2 | $46 |
| AbbVie | 2 | $39 |
| Myriad Genetic Laboratories, Inc. | 1 | $34 |
| Novartis | 1 | $27 |
| Halozyme Inc | 1 | $22 |
| Merck | 1 | $21 |
| Eisai Inc. | 1 | $21 |
| Novo Nordisk | 1 | $18 |
| Clarus Therapeutics Inc. | 1 | $17 |
| Olympus America Inc. | 1 | $16 |
| Tolmar Pharmaceuticals, Inc. | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIAFLEX$122
How this compares
$1,658 in reported general payments places this provider in the 75th percentile of 653 gerontology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 23 | $17,578 |
| MyrbetriqMirabegron | 15 | $15,938 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 59 | $1,624 |
| Tamsulosin Hcl | 95 | $1,206 |
| Oxybutynin Chloride ErOxybutynin Chloride | 31 | $652 |
| Testosterone Cypionate | 14 | $581 |
| Cephalexin | 42 | $532 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 21 | $170 |
| Ciprofloxacin Hcl | 29 | $132 |
| Anastrozole | 31 | $130 |
| Fluconazole | 27 | $111 |
| Ampicillin Trihydrate | 11 | $73 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $38 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $161 | $17,57823 claims |
| Astellas Pharma US IncMyrbetriq | $152 | $15,93815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 653 gerontology providers in Texas.
Other gerontology in Shenandoah
- Kimberly WelchCoppell$113K
- Tiffany KesslerDallas$84K
- Jennifer WestFort Worth$67K
- Meagan ChavarriaHouston$40K
- Bailey EstesAbilene$34K
- Scott ZelaHouston$28K
- Marissa Marti-SmithDallas$27K
- Andrew BargerAustin$22K
- Samantha BoggsGalveston$15K
- Amber ArmstrongAustin$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.